Rare Blood Disorders and Cancer Clinical Trials & Research

At Memorial Sloan Kettering, we have significant expertise in caring for people with rare blood disorders. We are committed to improving outcomes for people with these disorders. We believe that research offers the possibility of new treatments. We are focused on developing innovative ideas in our labs based on our understanding of the genetics of these diseases. Using this approach, we hope to find new drugs, or combinations of drugs, that can be introduced in clinical trials. We seek to effectively improve the overall condition of people with rare blood disorders and to reduce the impact of these diseases.

and/or
1 Clinical Trials found
A Study Using Immune Suppression Prior to Stem Cell Transplant for Children and Adults with Sickle Cell Disease or Beta-Thalassemia
Sickle cell disease and beta-thalassemia are blood diseases caused by a genetic change (mutation) in hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People with these diseases may be offered a stem cell transplant. Stem cell transplantation involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in the bone marrow.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau